Isolation and identification of major urinary metabolites of rifabutin in rats and humans

Drug Metabolism and Disposition

Volumn 25, Issue 8, 1997, Pages 963-969

  Utkin, Ilya ^a   Koudriakova, Tatiana ^b   Thompson, Toni ^b   Cottrell, Charles ^b   Iatsimirskaia, Eugenia ^b   Barry, John ^b   Vouros, Paul ^b   Gerber, Nicholas ^b  

^a OHIO STATE UNIVERSITY   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

20 HYDROXYRIFABUTIN; 25 O DEACETYLRIFABUTIN; 27 O DEMETHYLRIFABUTIN; 31 HYDROXYRIFABUTIN; 32 HYDROXYRIFABUTIN; CARBON 14; DRUG METABOLITE; PIPERIDINE DERIVATIVE; RIFABUTIN; UNCLASSIFIED DRUG;

ADULT; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG IDENTIFICATION; DRUG ISOLATION; DRUG METABOLISM; DRUG OXIDATION; DRUG URINE LEVEL; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; INTRAVENOUS DRUG ADMINISTRATION; LIPOPHILICITY; MALE; MASS SPECTROMETRY; NONHUMAN; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; RAT;

ADOLESCENT; ADULT; ANIMALS; ANTIBIOTICS, ANTITUBERCULAR; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; HUMANS; MALE; MASS SPECTROMETRY; MIDDLE AGED; RATS; RATS, SPRAGUE-DAWLEY; RIFABUTIN; SPECIES SPECIFICITY;

ANIMALIA;

EID: 0030848296     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. L. Marsili, C. R. Pasqualucci, A. Vigevani, B. Giola, G. Schioppacassi, and G. Oronzo: New rifamycins modified at positions 3 and 4. Synthesis, structure and biological evaluation. J. Antibiot. 34, 1033-1038 (1981).
2. R. J. O'Brien, M. A. Lyle, and D.E. Snider: Rifabutin (ansamycin LM 427): a new rifamycin-S derivative for the treatment of mycobacterial diseases. Rev. Infect. Dis. 9, 519-530 (1987).
3. L. B. Heifets and M. D. Iseman: Determination of in vitro susceptibility of mycobacteria to ansamycin. Am. Rev. Respir. Dis. 132, 710-711 (1985).
4. C. L. Woodley and J. O. Kilburn: In vitro susceptibility of Mycobacterium avium complex and Mycobacterium tuberculosis strains to a spiropiperidyl rifamycin. Am. Rev. Respir. Dis. 126, 586-587 (1982).
5. R. D. Moore and R. E. Chaisson: Survival analysis of two controlled trials of rifabutin prophylaxis against Mycobacterium avium complex in AIDS. AIDS 9, 1337-1342 (1995).
6. A. S. D. Nightingale, D. W. Cameron, F. M. Gordin, P. M. Sullam, D. L. Cohn, R. E. Chaisson, L. J. Eron, P. D. Sparti, B. Bihari, D. L. Kaufman, J. J. Stern, D. D. Pearce, W. G. Weinberg, A. LaMarka, and F. P. Siegal: Two controlled trials of rifabutin prophylaxis against Mycobacterium avium complex in AIDS. N. Engl. J. Med. 329, 828-833 (1993).
7. D. S. Maddix, K. B. Tallian, and P. S. Mead: Rifabutin: a review with emphasis on its role in the prevention of disseminated Mycobacterium avium complex infection. Ann. Pharmacother. 28, 1250-1254 (1994).
8. S. L. Chan, W. W. Yen, W. K. Ma, D. J. Girling, V. R. Aber, D. Felmingham, B. W. Allen, and D. A. Mitchison: The early bactericidal activity of rifabutin measured by sputum viable counts in Hong Kong patients with pulmonary tuberculosis. Tuber. Lung Dis. 73, 33-38 (1992).
9. M. Riva, S. Crippa, F. Di. Palma, A. M. Gerini, E. Soresi, and S. Scoccia: Disseminated tuberculosis of the central nervous system responsive to rifabutin. Ital. J. Neurol. Sci. 11, 163-169 (1990).
10. S. H. Gillespie, A. J. Baskerville, R. N. Davidson, D. Felmingham, and A. D. Bryceson: The serum rifabutin concentrations in a patient successfully treated for multi-resistant Mycobacterium tuberculosis infection. J. Antimicrob. Chemother. 25, 490-491 (1990).
11. 14C-rifabutin in animals and man. J. Antimicrob. Chemother. 26, 813-822 (1990).
12. 14C-rifabutin in rats. Antimicrob. Agents Chemother. 35, 1391-1396 (1991).
13. C. Cocchiara, M. Benedetti, G. P. Vicario, M. Ballabio, B. Gioia, S. Vioglio, and A. Vigevani: Urinary metabolites of rifabutin, a new antimycobacterial agent, in human volunteers. Xenobiotica. 19, 769-780 (1989).
14. A. Vigevani, M. Ballabio, B. Gioia, L. Marsili, S. Vioglio, and G. Franceschi: Identification of urinary metabolites of rifamycin LM 427 in man. J. Antibiot. 38, 1799-1802 (1985).
15. T. Koudriakova, E. Iatsimirskaia, S. Tulebaev, D. Spetie, I. Utkin, D. Mullet, T. Thompson, P. Vouros, and N. Gerber: In vivo disposition and metabolism by liver and enterocyte microsomes of the antitubercular drug rifabutin in the rat. J. Pharmacol. Exp. Ther. 279, 1300-1309 (1996).
16. E. Fontana, S. Giarda, S. Vioglio, and G. P. Vicario: Synthesis of carbon-14 labelled spiro-piperidyl-rifamycins (LM 118) and rifabutin (LM 427). J. Labelled Comp. Radiopharm. 24, 1337-1349 (1987).
17. E. Iatsimirskaia, S. Tulebaev, E. Storozhuk, I. Utkin, D. Smith, N. Gerber, and T. Koudriakova. Metabolism of rifabutin in human enterocyte and liver microsomes: Kinetic parameters, identification of enzyme systems, and drug interactions with macrolides and antifungal agents. Clin. Pharmacol. Ther. 61, 554-562 (1997).